The maker of Ozempic and Wegovy obesity drugs said some of the prices could come down, as President Trump called for drugmakers to immediately lower their prices for Medicaid. This comes as Novo ...

Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.

Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...

Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the ...

Detailed price information for Dividend Appreciation ETF Vanguard (VIG-A) from The Globe and Mail including charting and trades.

The results follow Novo’s worst weekly decline in its history after the company slashed its full-year guidance.

The Trump administration is launching a pressure campaign against prescription drugmakers in an effort to get them to lower ...

CMS often withholds coverage for reimbursement, disrupting the natural flow of the market and hindering access to proven ...

Weight loss medications such as Wegovy and Zepbound have garnered an enormous amount of attention recently for their ability to help some users lose significant amounts of weight relatively easily.

These tariffs would drastically undermine the price advantage Indian drug makers currently enjoy in the US, especially in ...